Improvement in growth after 1 year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: results of a multicenter, controlled, randomized, open clinical trial.

Plain-language guide to PMID 20522533 (2010): multicenter randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 20522533
Journal: Clinical journal of the American Society of Nephrology : CJASN
Year: 2010
Study type: Randomized Controlled Trial
Authors: Santos F et al. (13 authors)
DOI: 10.2215/CJN.07791109
Registered trial: NCT00184769

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Their aim was to evaluate the growth-promoting effect of growth hormone (GH) treatment in infants with chronic renal failure (CRF) and persistent growth retardation despite adequate nutritional and metabolic management.

Who Took Part

By PubMed's age tags, the people studied were infants, both men and women.

How the Study Was Run

In design terms this was a randomized, multicenter and parallel-group study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

Main outcome measures were body length, body weight, bone age, biochemical and hormonal analyses, renal function, bone mass, and adverse effects.

What Was Measured

PubMed files the paper under topics including Absorptiometry, Photon, Arm Bones, Biomarkers, Body Height, Bone Density, Chi-Square Distribution and Enzyme-Linked Immunosorbent Assay.

What This Means in Plain Language

The paper is a randomized, multicenter and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.